Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 30 Nov 2018

At a glance

  • Drugs XmAb-23104 (Primary)
  • Indications Acute myeloid leukaemia; B-cell lymphoma; Cancer; Haematological malignancies; Multiple myeloma; Neuroendocrine tumours
  • Focus Adverse reactions
  • Acronyms DUET-3
  • Sponsors Xencor

    • Most Recent Events

    • 23 Nov 2018 Status changed from planning to not yet recruiting.
    • 01 Mar 2018 New trial record
    • 27 Feb 2018 According to a Xencor media release, IND filling for this drug is expected in 2018 and initiation of this trial is expected in 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top